Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

Upstream Processing

Upstream Processing

Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Engineering Secretory (S)IgA to Facilitate Affinity Purification for Large Scale Downstream Processing.

Biotechnology journal·2026

Same author

Vernalization reveals distinct roles of FLOWERING LOCUS T homologs in floral transition of perennial Taraxacum koksaghyz.

Plant science : an international journal of experimental plant biology·2025

Same author

Characterisation of chikungunya virus neutralising monoclonal antibodies expressed in tobacco plants.

Journal of biotechnology·2025

Same author

TkSRPP3/4 interactors TkGGR1 and TkLIL3 link plastid-like organelles with isoprenoid metabolism in Taraxacum koksaghyz latex.

Plant cell reports·2025

Same author

Molecular basis of the explosive defence response in the bombardier beetle <i>Brachinus crepitans</i>.

Royal Society open science·2025

Same author

Mucosal immune responses to SARS-CoV-2 infection and COVID-19 vaccination.

Vaccine·2025

Search research articles

Related Experiment Video

Updated: May 14, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Target product selection - where can Molecular Pharming make the difference?

Mathew J Paul¹, Audrey Y H Teh, Richard M Twyman

¹The Molecular Immunology Unit, Infection and Immunity Research Centre, St. George's University of London, Cranmer Terrace, London SW17 0RE, United Kingdom.

Current Pharmaceutical Design

|February 12, 2013

Summary

This summary is machine-generated.

Molecular Pharming, using plant biotechnology, is gaining commercial momentum with recent successes in clinical trials and market approvals for plant-derived biopharmaceuticals. Careful product selection is key for sustainable growth in this field.

More Related Videos

Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit

Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit

Published on: June 28, 2013

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

Related Experiment Videos

Last Updated: May 14, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit

Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit

Published on: June 28, 2013

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

Area of Science:

Plant biotechnology
Molecular Pharming
Biopharmaceutical development

Background:

Recent advancements in Molecular Pharming have seen significant progress.
Key developments include successful clinical trials and regulatory approvals for plant-derived therapeutics.

Purpose of the Study:

To discuss current promising plant biotechnology approaches in Molecular Pharming.
To define product areas most likely to benefit from different Molecular Pharming technologies.

Main Methods:

Review of major developments in Molecular Pharming.
Analysis of diverse platform technologies and market demands.
Assessment of economic and technical suitability of plant-based approaches.

Main Results:

Successful Phase I clinical trial for influenza vaccines (USA).
Regulatory approval and Phase I trial completion for a plant-derived monoclonal antibody (Europe).
FDA approval for the first plant-derived biopharmaceutical (Protalix Biotherapeutics).

Conclusions:

Molecular Pharming shows increasing commercial viability with a growing product pipeline.
Strategic selection of target products is crucial for commercial sustainability.
Plant biotechnology offers a suitable approach for specific biopharmaceutical targets, though not universally applicable.